Maximizing outcomes in genitourinary cancers across the treatment continuum

BJU International

Volumn 107, Issue SUPPL. 2, 2011, Pages 1-12

  Fitzpatrick, John M ^a   Bellmunt, Joaquim ^b   Dreicer, Robert ^c   Fleshner, Neil E ^d   Logothetis, Christopher J ^e   Moul, Judd W ^f   Tombal, Bertrand ^g   Zlotta, Alexandre ^d  

^a MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^b HOSPITAL DEL MAR   (Spain)

^c TAUSSIG CANCER INSTITUTE   (United States)

^d UNIVERSITY HEALTH NETWORK   (Canada)

^e UNIVERSITY OF TEXAS   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

BCG VACCINE; BICALUTAMIDE; CARBOPLATIN; CISPLATIN; DOCETAXEL; DOXORUBICIN; DUTASTERIDE; ESTRAMUSTINE; FINASTERIDE; GEMCITABINE; GONADORELIN AGONIST; LEUPRORELIN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PLACEBO; PLATINUM COMPLEX; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR; VINBLASTINE; VINFLUNINE;

ARTICLE; BLADDER CANCER; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; CANCER SURVIVAL; CYSTECTOMY; DISTANT METASTASIS; DOSE RESPONSE; DRUG DOSE REDUCTION; EARLY INTERVENTION; EXTERNAL BEAM RADIOTHERAPY; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; MALE TYPE ALOPECIA; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROSTATECTOMY; SEXUAL DYSFUNCTION; TRANSURETHRAL RESECTION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYSTECTOMY; FEMALE; HIGH-INTENSITY FOCUSED ULTRASOUND ABLATION; HUMANS; MALE; MIDDLE AGED; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS; WATCHFUL WAITING;

EID: 79952524643     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10035.x     Document Type: Article

References (92)

1. Ferlay J, Parkin DM, Steliarova-Foucher E,. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765-81
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ,. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-49
3. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW,. Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2010; 60: 99-119
4. National Cancer Institute Surveillance Research Program SEER Stat software. URL (accessed November 2010)
5. Etzioni R, Tsodikov A, Mariotto A, et al. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008; 19: 175-81
6. Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int 2008; 101: 809-16 (Pubitemid 351347736)
7. Andriole GL, Crawford ED, Grubb RL 3rd, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
8. Schroder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
9. Aus G, Ahlgren G, Bergdahl S, Hugosson J,. Infection after transrectal core biopsies of the prostate-risk factors and antibiotic prophylaxis. Br J Urol 1996; 77: 851-5 (Pubitemid 27407594)
10. Rietbergen JB, Kruger AE, Kranse R, Schroder FH,. Complications of transrectal ultrasound-guided systematic sextant biopsies of the prostate: evaluation of complication rates and risk factors within a population-based screening program. Urology 1997; 49: 875-80 (Pubitemid 27246956)
11. Chen RC, Clark JA, Talcott JA,. Individualizing quality-of-life outcomes reporting: how localized prostate cancer treatments affect patients with different levels of baseline urinary, bowel, and sexual function. J Clin Oncol 2009; 27: 3916-22
12. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78 (Pubitemid 36833878)
13. Canfield SE,. Annual screening for prostate cancer did not reduce mortality from prostate cancer. Evid Based Med 2009; 14: 104-5
14. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men. Establishment of age-specific reference ranges. JAMA 1993; 270: 860-4 (Pubitemid 23234116)
15. Moul JW, Sun L, Hotaling JM, et al. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening. J Urol 2007; 177: 499-503, 504
16. Catalona WJ, Partin AW, Slawin KM, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA 1998; 279: 1542-7 (Pubitemid 28233009)
17. Wang R, Chinnaiyan AM, Dunn RL, Wojno KJ, Wei JT,. Rational approach to implementation of prostate cancer antigen 3 into clinical care. Cancer 2009; 115: 3879-86
18. Ross RK, Bernstein L, Lobo RA, et al. 5-alpha-reductase activity and risk of prostate cancer among Japanese and US white and black males. Lancet 1992; 339: 887-9
19. Hsing AW, Reichardt JK, Stanczyk FZ,. Hormones and prostate cancer: current perspectives and future directions. Prostate 2002; 52: 213-35 (Pubitemid 34791223)
20. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003; 349: 215-24 (Pubitemid 36859473)
21. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202
22. Cohen YC, Liu KS, Heyden NL, et al. Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. J Natl Cancer Inst 2007; 99: 1366-74 (Pubitemid 351767189)
23. Bostwick DG, Qian J, Civantos F, Roehrborn CG, Montironi R,. Does finasteride alter the pathology of the prostate and cancer grading? Clin Prostate Cancer 2004; 2: 228-35 (Pubitemid 38500693)
24. McDonnell TJ, Troncoso P, Brisbay SM, et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res 1992; 52: 6940-4 (Pubitemid 23006303)
25. Albertsen PC, Hanley JA, Fine J,. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101 (Pubitemid 40617061)
26. Berglund RK, Masterson TA, Vora KC, Eggener SE, Eastham JA, Guillonneau BD,. Pathological upgrading and up staging with immediate repeat biopsy in patients eligible for active surveillance. J Urol 2008; 180: 1964-7, 1967- 8
27. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31
28. Fleshner N, Gomella LG, Cookson MS, et al. Delay in the progression of low-risk prostate cancer: rationale and design of the Reduction by Dutasteride of Clinical Progression Events in Expectant Management (REDEEM) trial. Contemp Clin Trials 2007; 28: 763-9 (Pubitemid 47499254)
29. Catalona WJ, Smith DS,. 5-year tumor recurrence rates after anatomical radical retropubic prostatectomy for prostate cancer. J Urol 1994; 152: 1837-42 (Pubitemid 24322641)
30. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP, Barrett DM,. Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 1994; 152: 1850-7 (Pubitemid 24322643)
31. Chuang AY, Nielsen ME, Hernandez DJ, Walsh PC, Epstein JI,. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol 2007; 178: 1306-10 (Pubitemid 47368418)
32. Stephenson AJ, Scardino PT, Eastham JA, et al. Postoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2005; 23: 7005-12
33. Bolla M, van Poppel H, Collette L, et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-8 (Pubitemid 41140332)
34. Thompson IM Jr, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-35 (Pubitemid 44749360)
35. Wiegel T, Bottke D, Steiner U, et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-30
36. Thompson IM, Tangen CM, Paradelo J, et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-62
37. Leventis AK, Shariat SF, Kattan MW, Butler EB, Wheeler TM, Slawin KM,. Prediction of response to salvage radiation therapy in patients with prostate cancer recurrence after radical prostatectomy. J Clin Oncol 2001; 19: 1030-9 (Pubitemid 32176278)
38. Cropper CM,. The robot is in-and ready to operate. Business Week, 2005; March 14: 110-2
39. Barrett J,. Cutting edge. Newsweek 2005; 24: 50-4
40. Heidenreich A, Bolla M, Joniau S, et al.; European Association of Urology. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
41. Hu JC, Gu X, Lipsitz SR, et al. Comparative effectiveness of minimally invasive vs open radical prostatectomy. JAMA 2009; 302: 1557-64
42. Lepor H,. Status of radical prostatectomy in 2009: is there medical evidence to justify the robotic approach? Rev Urol 2009; 11: 61-70
43. Klotz L,. Robotic radical prostatectomy: Fools rush in, or the early bird gets the worm? Can Urol Assoc J 2007; 1: 87
44. Ficarra V, Novara G, Fracalanza S, et al. A prospective, non-randomized trial comparing robot-assisted laparoscopic and retropubic radical prostatectomy in one European institution. BJU Int 2009; 104: 534-9
45. Uchida T, Ohkusa H, Yamashita H, et al. Five years experience of transrectal high-intensity focused ultrasound using the Sonablate device in the treatment of localized prostate cancer. Int J Urol 2006; 13: 228-33
46. Petrylak DP, Tangen CM, Hussain MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 2004; 351: 1513-20 (Pubitemid 39315318)
47. Tannock IF, de Wit R, Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 2004; 351: 1502-12 (Pubitemid 39315317)
48. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF,. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008; 26: 242-5
49. Armstrong AJ, Garrett-Mayer ES, Yang YC, de Wit R, Tannock IF, Eisenberger M,. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin Cancer Res 2007; 13: 6396-403 (Pubitemid 350075029)
50. Berthold DR, Pond GR, Roessner M, de Wit R, Eisenberger M, Tannock AI,. Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study. Clin Cancer Res 2008; 14: 2763-7
51. Armstrong AJ, Garrett-Mayer E, Ou Yang YC, et al. Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer. J Clin Oncol 2007; 25: 3965-70 (Pubitemid 47477275)
52. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst 2006; 98: 516-21 (Pubitemid 43898814)
53. Armstrong AJ, Tannock IF, de Wit R, George DJ, Eisenberger M, Halabi S,. The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival. Eur J Cancer 2010; 46: 517-25
54. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R,. The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics 2003; 21: 1315-30 (Pubitemid 38041357)
55. Johansson SL, Cohen SM,. Epidemiology and etiology of bladder cancer. Semin Surg Oncol 1997; 13: 291-8 (Pubitemid 27332851)
56. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J,. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol 2008; 54: 303-14
57. Millan-Rodriguez F, Chechile-Toniolo G, Salvador-Bayarri J, Palou J, Vicente-Rodriguez J,. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J Urol 2000; 163: 73-8
58. van Rhijn BW, van der Kwast TH, Kakiashvili DM, et al. Pathological stage review is indicated in primary pT1 bladder cancer. BJU Int 2010; 106: 206-11
59. Dalbagni G, Vora K, Kaag M, et al. Clinical outcome in a contemporary series of restaged patients with clinical T1 bladder cancer. Eur Urol 2009; 56: 903-10
60. Zhang GK, Uke ET, Sharer WC, Borkon WD, Bernstein SM,. Reassessment of conservative management for stage T1N0M0 transitional cell carcinoma of the bladder. J Urol 1996; 155: 1907-9 (Pubitemid 26144082)
61. Skinner EC,. The best treatment for high-grade T1 bladder cancer is cystectomy. Urol Oncol 2007; 25: 523-5 (Pubitemid 350151907)
62. van der Aa MN, van Leenders GJ, Steyerberg EW, et al. A new system for substaging pT1 papillary bladder cancer: a prognostic evaluation. Hum Pathol 2005; 36: 981-6 (Pubitemid 41253384)
63. Orsola A, Trias I, Raventos CX, et al. Initial high-grade T1 urothelial cell carcinoma: feasibility and prognostic significance of lamina propria invasion microstaging (T1a/b/c) in BCG-treated and BCG-non-treated patients. Eur Urol 2005; 48: 231-8 (Pubitemid 40957095)
64. Bohle A, Jocham D, Bock PR,. Intravesical bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 2003; 169: 90-5 (Pubitemid 35461559)
65. Sylvester RJ, van der MA, Lamm DL,. Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 2002; 168: 1964-70
66. Martinez-Pineiro JA, Flores N, Isorna S, et al. Long-term follow-up of a randomized prospective trial comparing a standard 81 mg dose of intravesical bacille Calmette-Guerin with a reduced dose of 27 mg in superficial bladder cancer. BJU Int 2002; 89: 671-80 (Pubitemid 34429530)
67. Martinez-Pineiro JA, Martinez-Pineiro L, Solsona E, et al. Has a 3-fold decreased dose of bacillus Calmette-Guerin the same efficacy against recurrences and progression of T1G3 and Tis bladder tumors than the standard dose? Results of a prospective randomized trial. J Urol 2005; 174: 1242-7 (Pubitemid 41318691)
68. Witjes JA,. Management of BCG failures in superficial bladder cancer: a review. Eur Urol 2006; 49: 790-7
69. Fernandez-Gomez J, Solsona E, Unda M, et al. Prognostic factors in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin: multivariate analysis of data from four randomized CUETO trials. Eur Urol 2008; 53: 992-1001
70. Zlotta AR, Fleshner NE, Jewett MA,. The management of BCG failure in non-muscle-invasive bladder cancer: an update. Can Urol Assoc J 2009; 3: S199-205
71. Chung PW, Bristow RG, Milosevic MF, et al. Long-term outcome of radiation-based conservation therapy for invasive bladder cancer. Urol Oncol 2007; 25: 303-9 (Pubitemid 47031001)
72. Lamm DL, Blumenstein BA, Crissman JD, et al. Maintenance bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 2000; 163: 1124-9 (Pubitemid 30169376)
73. Zlotta AR, Drowart A, Van Vooren JP, et al. Evolution and clinical significance of the T cell proliferative and cytokine response directed against the fibronectin binding antigen 85 complex of bacillus Calmette-Guerin during intravesical treatment of superficial bladder cancer. J Urol 1997; 157: 492-8 (Pubitemid 27026824)
74. Zlotta AR, van Vooren JP, Huygen K, et al. What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary? Eur Urol 2000; 37: 470-7 (Pubitemid 30157810)
75. Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet 2003; 361: 1927-34
76. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data: Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Eur Urol 2005; 48: 202-5; 205- 6
77. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Adjuvant chemotherapy for invasive bladder cancer (individual patient data). Cochrane Database Syst Rev 2006; CD006018
78. Saxman SB, Propert KJ, Einhorn LH, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997; 15: 2564-9 (Pubitemid 27289886)
79. Sternberg CN, de Mulder P, Schornagel JH, et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur J Cancer 2006; 42: 50-4 (Pubitemid 41814532)
80. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol 2005; 23: 4602-8 (Pubitemid 46224062)
81. Stenzl A, Cowan NC, De Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol 2009; 55: 815-25
82. Dash A, Galsky MD, Vickers AJ, et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 2006; 107: 506-13 (Pubitemid 44107210)
83. Bellmunt J, Ribas A, Eres N, et al. Carboplatin-based versus cisplatin-based chemotherapy in the treatment of surgically incurable advanced bladder carcinoma. Cancer 1997; 80: 1966-72 (Pubitemid 27479792)
84. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase 2 trial. Eur Urol 2007; 52: 134-41 (Pubitemid 46803003)
85. Petrioli R, Frediani B, Manganelli A, et al. Comparison between a cisplatin-containing regimen and a carboplatin-containing regimen for recurrent or metastatic bladder cancer patients. A randomized phase II study. Cancer 1996; 77: 344-51
86. De Santis M, Bellmunt J, Mead G, et al. Randomized phase II/III trial assessing gemcitabine/carboplatin and methotrexate/carboplatin/vinblastine in patients with advanced urothelial cancer "unfit" for cisplatin-based chemotherapy: phase II-results of EORTC study 30986. J Clin Oncol 2009; 27: 5634-9
87. Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A,. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001; 92: 2993-8 (Pubitemid 33136193)
88. Vaughn DJ, Broome CM, Hussain M, Gutheil JC, Markowitz AB,. Phase II trial of weekly paclitaxel in patients with previously treated advanced urothelial cancer. J Clin Oncol 2002; 20: 937-40 (Pubitemid 34141835)
89. McCaffrey JA, Hilton S, Mazumdar M, et al. Phase II trial of docetaxel in patients with advanced or metastatic transitional-cell carcinoma. J Clin Oncol 1997; 15: 1853-7 (Pubitemid 27209514)
90. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer 1998; 34: 1208-12 (Pubitemid 28342111)
91. Bellmunt J, Theodore C, Demkov T, et al. Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract. J Clin Oncol 2009; 27: 4454-61
92. Bellmunt J, Choueiri TK, Fougeray R, et al. Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. J Clin Oncol 2010; 28: 1850-5